Unknown

Dataset Information

0

Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.

ABSTRACT:

SUBMITTER: Wei AH 

PROVIDER: S-EPMC9851684 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.

Wei Andrew H AH   Roboz Gail J GJ   Kantarjian Hagop M HM  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20210604 25

Similar Datasets

Unknown Venetoclax Resistance in Acute Myeloid Leukemia.
| S-EPMC10969100 | biostudies-literature
Unknown Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
| S-EPMC8045494 | biostudies-literature
Unknown Venetoclax-containing regimens in acute myeloid leukemia.
| S-EPMC7882757 | biostudies-literature
Unknown Venetoclax-based therapies for acute myeloid leukemia.
| S-EPMC6581210 | biostudies-literature
Unknown Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential.
| S-EPMC12672737 | biostudies-literature
Unknown Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
| S-EPMC10618724 | biostudies-literature
Unknown Harnessing Immune Response in Acute Myeloid Leukemia.
| S-EPMC10532363 | biostudies-literature
Unknown Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.
| S-EPMC9278306 | biostudies-literature
Unknown Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
| S-EPMC7873265 | biostudies-literature
Unknown Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
| S-EPMC7124979 | biostudies-literature